Plain-English translation of NCT05947890 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new tuberculosis vaccine called in people aged 12–55, both with and without HIV. Researchers want to understand whether the medication is safe and whether it helps the body build protection against tuberculosis. You would receive a single small injection under the skin and be followed for 48 weeks.
Tuberculosis remains a serious threat worldwide, especially for people living with HIV. Current vaccines have limited effectiveness, so researchers are developing this new treatment to offer better protection and prevent TB disease in vulnerable populations.
You likely qualify if…
You likely don't qualify if…
You will receive one small injection under the skin in your upper arm at the first visit. After that, you will return to the clinic for follow-up visits over the next 48 weeks so researchers can check how your body responds to the vaccine, take blood tests, and watch for any side effects. The study compares this new vaccine to the standard vaccine to see which one works better.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
South Africa